Stock Detail
THERMOGENESIS CORP
Electronics
KOOL @ Yahoo Finance | KOOL Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.00 | $1.00 | $0.00 | 0.00% | 0.00 | $1.00 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.00 | $0.96 | 18,727 | 16.37M | 47,899 | -4.17 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 1.03 | 1.02 | 0.99 | 0.98 | 0.95 |
Stock Profile
Thermogenesis Corp. engages in the design, manufacture, and distribution of blood processing devices and single-use sterile blood processing disposables that enable the manufacture of therapeutic biological products. Its therapeutic products include hematopoietic stem cells from placental/cord blood for bone marrow rescue transplants; blood protein surgical sealants to arrest surgical bleeding or bond excised tissue; and platelet gels to accelerate the healing of damaged bones and chronic dermal wounds. The company's products portfolio comprises BioArchive System, a robotic liquid nitrogen storage system with integrated controlled rate freezer process to cryopreserve and archive units of cord blood stem cells in liquid nitrogen; BioArchive accessories and sterile single use disposables, such as over wrap bags, sealers, expressers, a manual retrieval device, protective storage canisters, processing bags, and freezing bags; ThermoLine Ultra-Rapid Plasma Thawers used for homogeneous thawing of frozen red blood cells or fresh frozen plasma before their transfusion; Ultra-Rapid Plasma Freezers that optimize plasma freezing through liquid heat transfer and uniform freezing technologies; AutoXpress System, designed to provide cord blood banks a semiautomated means of collecting mono-nuclear cells from cord blood into a fixed volume within a closed sterile bag; CryoSeal FS System, which produces fibrin sealant components from a single unit of autologous or single donor plasma in about one hour; and thrombin processing device, a sterile single use disposable that can produce approximately 8 ml of activated thrombin from an 11 ml aliquot of the patient's blood or blood plasma. The company markets its products through direct sales force and independent distributors to hospitals and blood banks located in the United States, Europe, Japan, Asia-Pacific, Canada, and Latin America. ThermoGenesis was founded in 1985 and is based in Rancho Cordova, California.